Miriam

Miriam is a biotechnology company developing a high-sensitivity liquid biopsy platform for the early detection of cancer. By leveraging advanced RNA sequencing and machine learning, the company aims to identify cancer-specific signals in the blood at their earliest, most treatable stages. Their technology focuses on the transcriptome to uncover novel biomarkers that traditional DNA-based liquid biopsies might miss. Miriam's mission is to transform cancer care from reactive treatment to proactive early intervention through accessible and accurate screening. The company's platform is designed to be pan-cancer, targeting a wide range of malignancies with a single blood draw. Headquartered in San Francisco, Miriam is backed by leading venture capital firms including Khosla Ventures and General Catalyst.